Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 11/06/2024 BST 5-day change 1st Jan Change
187,600 KRW -2.60% Intraday chart for Celltrion, Inc. -0.27% -6.90%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan MT
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024. CI
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million. CI
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe CI
Celltrion's Q1 Attributable Profit Slumps 86% MT
Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
Celltrion, Inc. announces an Equity Buyback for 436,047 shares. CI
Celltrion, Inc. authorizes a Buyback Plan. CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024. CI
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million. CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US MT
Celltrion's Autoimmune Disease Treatment Hits US Markets MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed MT
Celltrion Announces 75 Billion Won Share Buyback Plan MT
Celltrion, Inc. announces an Equity Buyback for 425,895 shares. CI
Celltrion, Inc. authorizes a Buyback Plan. CI
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25% MT
Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease CI
South Korean Shares Close Lower on Hotter-Than-Expected US Inflation Data MT
Celltrion Pursues EMA Approval for Actemra Biosimilar MT
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates CI
Celltrion Strikes Key Anti-Cancer Treatment Deals Across Europe MT
Chart Celltrion, Inc.
More charts
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
187,600 KRW
Average target price
231,882 KRW
Spread / Average Target
+23.60%
Consensus
  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. News Celltrion, Inc.
  5. South Korean Shares Close Higher as Investors Look Beyond Further Rate Hike Decision by US Fed; Celltrion Adds 1%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW